Arovella Therapeutics Limited (ASX:ALA)

Arovella Therapeutics Revenue

In the fiscal year ending June 30, 2026, Arovella Therapeutics had annual revenue of 4.30M AUD with 24.94% growth. Arovella Therapeutics had revenue of 3.21M in the half year ending December 31, 2025, with 65.10% growth.

• Revenue: 4.30M
• Revenue Growth: +12.23%
• P/S Ratio: 18.28
• Revenue / Employee: 159.19K
• Employees: 27
• Market Cap: 78.57M

Revenue Chart

Chart

Chart

Revenue History

Fiscal Year End	Revenue	Change	Growth
Jun 30, 2026	4.30M	858.05K	24.94%
Jun 30, 2025	3.44M	1.49M	76.22%
Jun 30, 2024	1.95M	497.46K	34.20%
Jun 30, 2023	1.45M	1.16M	391.76%
Jun 30, 2022	295.81K	-693.91K	-70.11%

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Aug 21, 2026

Data Sources Report a data error